DURHAM, N.C.--(BUSINESS WIRE)--April 26, 2006--Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH - News) announced today the initiation of a Phase 2 clinical trial to evaluate Inspire’s drug candidate, INS50589 Antiplatelet, in patients undergoing coronary artery bypass graft (CABG) surgery utilizing a cardiopulmonary bypass pump.
